Acute exacerbation of idiopathic pulmonary fibrosis after SARS-CoV-2 vaccination
- PMID: 35144990
- PMCID: PMC8832376
- DOI: 10.1183/13993003.02806-2021
Acute exacerbation of idiopathic pulmonary fibrosis after SARS-CoV-2 vaccination
Abstract
Although the association between acute exacerbation of interstitial lung disease and vaccination is not yet clarified, this is the first case report describing the possibility that SARS-CoV-2 vaccination may trigger acute exacerbation https://bit.ly/3tpu6Cz
Conflict of interest statement
Conflict of interest: T. Bando, R. Takei, Y. Mutoh, H. Sasano, Y. Yamano, T. Yokoyama, T. Matsuda, K. Kataoka and T. Kimura have nothing to disclose. Y. Kondoh reports funding from Nippon Boehringer Ingelheim Co. Ltd, consulting fees from Asahi Kasei Pharma Corp., Shionogi & Co. Ltd, Boehringer Ingelheim Co. Ltd, Janssen Pharmaceutical K.K., Healios K.K. and Taiho Pharmaceutical Co. Ltd, and payment for lectures from Asahi Kasei Pharma Corp., Shionogi & Co. Ltd, Boehringer Ingelheim Co. Ltd, Actelion Pharmaceuticals Ltd, DAIICHI SANKYO Co. Ltd, Bristol Myers Squibb, AstraZeneca K.K., Eisai inc., KYORIN Pharmaceutical Co. Ltd, Mitsubishi Tanabe Pharma and Novartis Pharma K.K., outside the submitted work.
Figures

Comment on
-
Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study.Int J Gen Med. 2021 Apr 19;14:1389-1401. doi: 10.2147/IJGM.S310497. eCollection 2021. Int J Gen Med. 2021. PMID: 33907443 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous